<DOC>
	<DOCNO>NCT01783613</DOCNO>
	<brief_summary>Cystic Fibrosis ( CF ) congenital disease secondary abnormal function CFTR . Patients CF alteration essential fatty acid , Arachidonic Acid ( AA ) increase Docosahexanoic Acid ( DHA ) decrease ratio ω-6/ ω-3 elevate , alteration stimulate chronic bad regulate state inflammation . For porpoise , fase IV trial , multicentric , control , double blind , placebo parallel patient elder two month old randomize received every day dietetically supplement DHA placebo , do 12 month . The trial principal objective prove long term supplementation could decrease contrast placebo .</brief_summary>
	<brief_title>Eficacy Long-term Suplementation With Docosahexaenoic Acid Patients With Cystic Fibrosis</brief_title>
	<detailed_description />
	<mesh_term>Fibrosis</mesh_term>
	<mesh_term>Cystic Fibrosis</mesh_term>
	<criteria>Diagnosed cystic fibrosis 2 month age Tolerance clinical supplementation DHA Clinical situation stable Changes routine treatment 2 week prior baseline Admission hospital administration oral intravenous antibiotic within 2 week inclusion</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
</DOC>